MOLN

Molecular Partners

5.08 USD
-0.14
2.68%
At close Dec 20, 4:00 PM EST
1 day
-2.68%
5 days
-6.62%
1 month
-2.31%
3 months
7.40%
6 months
-53.86%
Year to date
21.82%
1 year
13.39%
5 years
-74.15%
10 years
-74.15%
 

About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Employees: 167

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.03% less ownership

Funds ownership: 2.35% [Q2] → 2.31% (-0.03%) [Q3]

32% less capital invested

Capital invested by funds: $6.19M [Q2] → $4.2M (-$1.98M) [Q3]

38% less funds holding

Funds holding: 8 [Q2] → 5 (-3) [Q3]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Research analyst outlook

We haven’t received any recent analyst ratings for MOLN.

Financial journalist opinion

Based on 3 articles about MOLN published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will attend and present the Company's latest developments and outlook for 2025 at two upcoming investor conferences in January.
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet
The consensus price target hints at an 80.7% upside potential for Molecular Partners AG Sponsored ADR (MOLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet
Neutral
GlobeNewsWire
2 weeks ago
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
Neutral
GlobeNewsWire
1 month ago
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Neutral
GlobeNewsWire
1 month ago
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
Neutral
GlobeNewsWire
1 month ago
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the pricing of an underwritten offering in the United States of 3,642,988 American Depositary Shares (“ADSs”) representing 3,642,988 ordinary shares at an offering price of $5.49 per ADS, for total gross proceeds of approximately $20.0 million. All of the ADSs to be sold in the offering will be offered by Molecular Partners. The offering is expected to close on October 29, 2024, subject to customary closing conditions.
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
Neutral
GlobeNewsWire
2 months ago
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the strengthening of a previously announced co-development agreement with Orano Med, a clinical-stage radiopharmaceutical company developing targeted alpha therapies with lead-212 (212Pb), where both companies will develop and market 212Pb-based Radio-DARPin Therapeutics for the treatment of cancer.
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Neutral
GlobeNewsWire
2 months ago
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision attributes for alpha radiation therapy Molecular Partners and Orano Med preparing for clinical entry in 2025  ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art.
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Neutral
GlobeNewsWire
2 months ago
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40) shows intended and marked tumor microenvironment modulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will introduce proof-of-concept data for its new CD3 Switch-DARPin designed to overcome current T cell engager challenges in solid tumors, as well as present additional analyses from its Phase 1 study of MP0317 in patients with advanced solid tumors, at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 8-10 in Houston, TX.
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
Neutral
GlobeNewsWire
2 months ago
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present on its lead-212 (212Pb)-labeled Radio-DARPin Therapeutic (RDT) targeting delta-like ligand 3 (DLL3) co-developed with Orano Med, at the European Assocation of Nuclear Medicine (EANM) Congress which runs October 19-23, 2024 in Hamburg, Germany.
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Charts implemented using Lightweight Charts™